A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and

PF 06826647 in Adults With Hidradenitis Suppurativa

 

ID# NCT04092452

​

Recruitment Status:  recruiting as of August 2020.

 

Estimated Completion Date: Feb. 2, 2022

 

Sponsors and Collaborators: Pfizer

​

Information provided by (Responsible Party): Pfizer

​

Brief Summary: This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.

​

Please link complete details https://clinicaltrials.gov/ct2/show/NCT04092452

​

Locations:  multiple locations please refer to link above for further information.

​

Contact: Pfizer CT.gov Call Center, 1-800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com